Q-Sera’s technology is based upon research emanating from the University of Queensland and is patent protected.
Family 1 Priority Date Sept 2010
This patent covers all prothrombin activators from snake venom including naturally occurring and recombinant versions in blood collection tubes for the production of serum for biochemical analysis.
August 2019: Patent granted or approved in US, EU, Japan, China, Canada, Mexico, Russia, South Africa and Australia.
Patent pending in South Korea, India, Israel and Brazil.
Family 2 Priority Date Oct 2014
'Improved Clotting Composition'
Covers formulations to enhance the temperature and irradiation stability of snake venom prothrombin activators in blood collection tubes.